Iberdomide (CC-220)

製品コードS8760 バッチS876002

化学情報

	Synonyms	N/A	Storage (From the date of receipt)	3 years -20°C powder
	化学式	C₂₅H₂₇N₃O₅
	分子量	449.50	CAS No.	1323403-33-3
Solubility (25°C)*	体外	DMSO	90 mg/mL (200.22 mM)
		Ethanol	5 mg/mL (11.12 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	Iberdomide (CC-220)は、CRL4CRBN E3ユビキチンリガーゼ複合体の一部であるセレブロンを標的とする新規経口免疫調節化合物であり、競合的TR-FRETアッセイにおいて60 nMのIC50を示します。Iberdomide (CC-220)は、抗腫瘍活性と免疫刺激活性を伴うアポトーシスを誘導します。
in vitro	Iberdomide (CC-220) is a potent anti-proliferative and pro-apoptotic compound that shows activity in several MM cell line categories. In cellular degradation assays, treatment with this compound results in the loss of Ikaros protein levels with an EC50 of 1 nM. It is similarly potent toward Aiolos, with an EC50 of 0.5 nM. It induces PBMC-mediated killing of all MM cell lines regardless of the level of Cereblon expression and cell autonomous sensitivity. This compound acts through binding of Cereblon, leading to the degradation of the hematopoietic transcription factors Ikaros and Aiolos, followed by disruption of the MM promoting c-Myc/IRF4 axis.

製品説明

Iberdomide (CC-220)は、CRL4CRBN E3ユビキチンリガーゼ複合体の一部であるセレブロンを標的とする新規経口免疫調節化合物であり、競合的TR-FRETアッセイにおいて60 nMのIC50を示します。Iberdomide (CC-220)は、抗腫瘍活性と免疫刺激活性を伴うアポトーシスを誘導します。

in vitro

Iberdomide (CC-220) is a potent anti-proliferative and pro-apoptotic compound that shows activity in several MM cell line categories. In cellular degradation assays, treatment with this compound results in the loss of Ikaros protein levels with an EC50 of 1 nM. It is similarly potent toward Aiolos, with an EC50 of 0.5 nM. It induces PBMC-mediated killing of all MM cell lines regardless of the level of Cereblon expression and cell autonomous sensitivity. This compound acts through binding of Cereblon, leading to the degradation of the hematopoietic transcription factors Ikaros and Aiolos, followed by disruption of the MM promoting c-Myc/IRF4 axis.

プロトコル(参考用のみ)

細胞アッセイ	細胞株	DF15 cells
	濃度	60 nM
	反応時間	5 h
	実験の流れ	Cells were treated with Iberdomide (CC-220) for 5 h before harvest.
動物実験	動物モデル	Transgenic mice
	投薬量	10 mg/kg
	投与方法	o.g.

参考

https://pubmed.ncbi.nlm.nih.gov/28425720/
http://www.bloodjournal.org/content/128/22/1591?sso-checked=true
https://pubmed.ncbi.nlm.nih.gov/34258584/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities [ Cell Rep Med, 2025, S2666-3791(25)00102-8]	PubMed: 40147445
Novel Cereblon-Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus- Associated Lymphomas In Vitro [ J Med Virol, 2025, 97(8):e70537]	PubMed: 40767544
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wildtype p53 to Exert the Dominant-Negative Effect [ Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136]	PubMed: 40163352
Role of Rac1 in p53-Related Proliferation and Drug Sensitivity in Multiple Myeloma [ Cancers (Basel), 2025, 17(3)461]	PubMed: 39941828
Mapping the IMiD-dependent cereblon interactome using BioID-proximity labelling [ FEBS J, 2024, 10.1111/febs.17196]	PubMed: 38975872
Degradome analysis to identify direct protein substrates of small-molecule degraders [ bioRxiv, 2024, 10.1101/2024.01.28.577572]	PubMed: none
IMiDs Augment CD3-Bispecific Antibody-Induced CD8+ T-Cell Cytotoxicity and Expansion by Enhancing IL2 Production [ Mol Cancer Ther, 2023, 22(5):659-666]	PubMed: 36822576
Lenalidomide bypasses CD28 co-stimulation to reinstate PD-1 immunotherapy by activating Notch signaling [ Cell Chem Biol, 2022, S2451-9456(22)00204-5]	PubMed: 35732177
Tyrphostin AG1024 Suppresses Coronaviral Replication by Downregulating JAK1 via an IR/IGF-1R Independent Proteolysis Mediated by Ndfip1/2_NEDD4-like E3 Ligase Itch [ Pharmaceuticals (Basel), 2022, 15(2)241]	PubMed: 35215353
Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells [ Hemasphere, 2021, 5(7):e602]	PubMed: 34136753

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。